Stock Chart

GRCE

$2.07 +1.47%
Score: 45.2 HOLD
Pro
Screener
Vol: 0.64x (vs SPY: 0.6x | vs QQQ: 0.6x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 02, 2026
Symmetrical Triangle Bullish scenario quality 71/100
Measured-move target $2.2 (+6.1%) · apex ~18 bars ahead
Historically breaks up 54% overall; 71% up when formed in a downtrend (n=131)
Pattern detection is automated and probabilistic — a scenario map for levels, not a buy/sell signal. Rails, projected path and target are drawn on the chart below.
Technical Chart
OVERLAYS
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER
SETTINGS
Active (2)
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About GRCE - Grace Therapeutics, Inc. Common Stock

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.

Key Statistics

Market Cap $43M

More GRCE Analysis

Buy or Sell Analysis Price Prediction AI Analysis Fair Price Options Advisor Trendline Analysis

This GRCE stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track GRCE's price movements with trendlines, gamma walls, and key support/resistance levels.